Skip to main content

Table 1 Summary of baseline demographics, clinical characteristics, and analysis subgroups

From: Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials

  Mepolizumab (100 mg SC) Placebo Total
N = 468 N = 468 N = 936
Overall population
 Mean (SD) age, years 50.4 (14.25) 50.9 (13.55) 50.6 (13.90)
 Female, n (%) 265 (57) 283 (60) 548 (59)
 Mean (SD) % predicted FEV1 58.9 (16.74) 60.1 (16.93) 59.5 (16.84)
 Mean (SD) SGRQ total score 47.6 (18.64) 46.5 (19.25) 47.1 (18.94)
 Mean (SD) ACQ-5 score 2.25 (1.17) 2.21 (1.18) 2.23 (1.17)
 Receiving maintenance OCS therapy, n (%) 116 (25) 111 (24) 227 (24)
 Exacerbations in previous year, n (%)
  2 248 (53) 273 (58) 521 (56)
  3 96 (21) 94 (20) 190 (20)
  ≥ 4 124 (26) 101 (22) 225 (24)
 Geometric mean (SD log) eosinophil count, cells/μL 320 (0.965) 340 (0.929) 330 (0.947)
Subgroups, n (%)
 Age of asthma onset ( years)
  < 18 132 (28) 122 (26) 254 (27)
  18– < 40 173 (37) 172 (37) 345 (37)
  ≥ 40 162 (35) 174 (37) 336 (36)
 Lung function
  ≤ 60% predicted FEV1 245 (52) 244 (52) 489 (52)
  > 60–80% predicted FEV1 177 (38) 177 (38) 354 (38)
  > 80% predicted FEV1 46 (10) 47 (10) 93 (10)
 Airway reversibility
  na 457 460 917
  Reversibleb 312 (68) 299 (65) 611 (67)
  Non-reversiblec 145 (32) 161 (35) 306 (33)
 Allergen sensitivity
  na 454 457 911
  Sensitivity to ≥ 1 allergen 215 (47) 216 (47) 496 (54)
  Sensitivity to ≥ 1 seasonal allergen 144 (32) 146 (32) 290 (32)
 Asthma control
  na 465 462 927
  Uncontrolled asthmad 334 (72) 314 (68) 648 (70)
  Partially or fully controlled asthmae 131 (28) 148 (32) 279 (30)
  1. ACQ-5 Asthma Control Questionnaire, 5 item, FEV1 forced expiratory volume in 1 s, SC subcutaneous, SD standard deviation
  2. aNot all patients had data available on airway reversibility, asthma control and allergen sensitivity; those without ≥ 1 result were not included in the relevant subanalyses
  3. bDefined as patients with a ≥ 12% change in FEV1
  4. cDefined as patients with a < 12% change in FEV1
  5. dDefined as an ACQ-5 score ≥ 1.5
  6. edefined as an ACQ-5 score < 1.5